Children with asthma showed significantly lower levels of the antimicrobial peptide beta-defensin 2 in their saliva after four weeks of corticosteroid inhaler treatment.
Significant decrease in salivary beta-defensin 2After 4 weeks of inhaled corticosteroid therapy in asthmatic children, with no change in salivary flow rate
What the researchers found
Salivary beta-defensin 2 levels were significantly lower in children with asthma after 4 weeks of inhaled corticosteroid therapy compared to pre-treatment levels. Salivary flow rate did not change significantly between the two time points, indicating the reduction in this antimicrobial peptide was not simply due to reduced saliva production but likely a direct effect of corticosteroid treatment on defensin expression.
Why it matters
Beta-defensin 2 is a key antimicrobial peptide in the mouth's innate immune defense. Its reduction after corticosteroid inhaler use could help explain why asthmatic children on inhaler therapy are more susceptible to oral infections like candidiasis. This finding supports the recommendation for regular dental monitoring in these patients.
The numbers in context
Saliva sampled at 2 time points · 4 weeks of corticosteroid inhaler therapy · Significant decrease in beta-defensin 2 · No change in salivary flow rate
How the study worked
Cohort study of children diagnosed with asthma at a children's medical center. Saliva samples were collected at diagnosis (before treatment) and again 4 weeks after starting inhaled corticosteroid therapy. Beta-defensin 2 levels were measured using ELISA, and salivary flow rate was also assessed at both time points.
Who was studied
Children diagnosed with asthma at a children's medical center who were prescribed inhaled corticosteroid therapy
What this study cannot tell us
The abstract does not report the sample size, specific beta-defensin 2 concentrations, or effect sizes. The 4-week follow-up period is relatively short, so longer-term effects are unknown. The study lacked a control group of healthy children or asthmatic children not receiving corticosteroids, making it harder to isolate the drug's effect from disease progression.
How to read the evidence
This is a cohort study with before-and-after measurements in the same patients, providing moderate evidence. However, the lack of a control group and unreported sample size limit the strength of conclusions.
When this study was published
Published in 2023, this is recent research contributing to the growing understanding of how common respiratory medications affect oral antimicrobial peptide levels.
The bigger picture
Antimicrobial peptides like beta-defensin 2 are part of the body's first line of defense against pathogens. Understanding how common medications like corticosteroid inhalers affect these peptides is important for managing side effects — particularly oral candidiasis and dental problems — that are well-documented in asthmatic children. This research connects the dots between a widely used therapy and a specific molecular change in oral immunity.
Questions still open
- Does the reduction in salivary beta-defensin 2 correlate with increased rates of oral infections or dental caries in these children?
- Do beta-defensin 2 levels recover after discontinuing corticosteroid inhaler therapy or with mouth-rinsing protocols?
- Are other salivary antimicrobial peptides similarly affected by inhaled corticosteroids?
Common questions
What is beta-defensin 2 and what does it do in the mouth?
Should parents be concerned about their child's oral health when using asthma inhalers?
Read the original research
Decreased salivary beta-defensin 2 in children with asthma after treatment with corticosteroid inhaler.
European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry, 24(2), 249-254
Citation
Moosavi, M-S; Hosseinizade, P-S; Panahi, G; Shariat, M. (2023). Decreased salivary beta-defensin 2 in children with asthma after treatment with corticosteroid inhaler.. European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry, 24(2), 249-254. https://doi.org/10.1007/s40368-022-00776-w